Asston Pharmaceuticals IPO Allotment Status

How to Check Asston Pharmaceuticals IPO Allotment Status?

Asston Pharmaceuticals Limited, incorporated in 2019, is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally, offering a diverse range of products including tablets, capsules, sachets, and syrups with product portfolio encompassing various therapeutic categories such as analgesics, antibiotics, antifungals, vitamins, and more, manufacturing pharmaceutical products for direct sales and also on contract manufacturing or loan license basis primarily working on principle-to-principle approach with various marketers, FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards ensuring high-quality manufacturing with products including Albendazole USP 400 mg, Diclofenac 100 mg, Ibuprofen, paracetamol, and Ferrovit Syrup, employing 46 permanent employees and 6 contractual employees as of July 3, 2025.

The Asston Pharmaceuticals IPO comes with a total issue size of ₹27.56 crore, comprising entirely a fresh issue of 22.41 lakh shares. The IPO opened on July 9, 2025, and closed on July 11, 2025. The allotment for the Asston Pharmaceuticals IPO is expected to be finalized on Monday, July 14, 2025. The Asston Pharmaceuticals share price is set at ₹123 per share (fixed price).

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Steps to Check Asston Pharmaceuticals IPO Allotment Status on Registrar Site

• Visit the Maashitla Securities Private Limited website 
• Select "Asston Pharmaceuticals IPO" from the dropdown menu on the allotment status page
• Enter your PAN ID, Demat Account Number, or Application Number in the designated field
• Complete the captcha verification process and click on the "Submit" button to view your allotment status

Steps to Check Asston Pharmaceuticals IPO Allotment Status on BSE SME

• Navigate to the BSE IPO Allotment Status Page
• Choose "Asston Pharmaceuticals IPO" from the list of active IPOs in the dropdown menu
• Input your Application Number and PAN ID in the required fields
• Verify the captcha and click "Search" to check your allotment status

Asston Pharmaceuticals IPO Subscription Status

Asston Pharmaceuticals IPO received exceptional investor interest, being subscribed 186.40 times overall. The subscription showed overwhelming confidence across all categories in the Asston Pharmaceuticals stock price potential. Here is a category-wise breakdown of the subscription as of 4:59:34 PM on July 11, 2025:

• Retail Category: 171.78 times
• Non-Institutional Investors (NII): 353.10 times
• QIB Category: 85.76 times

Asston Pharmaceuticals Share Price and Investment Details

The Asston Pharmaceuticals stock price is set at ₹123 per share (fixed price) with a minimum lot size of 1,000 shares. The minimum investment required for retail investors is ₹2,46,000 for 2 lots (2,000 shares), while HNI investors need to invest a minimum of ₹3,69,000 for 3 lots (3,000 shares). Given the exceptional subscription response of 186.40 times overall, with all categories being heavily oversubscribed including retail at 171.78 times, NII at 353.10 times, and QIB at 85.76 times, the Asston Pharmaceuticals share price is expected to list at significant premium.

Utilisation of IPO Proceeds
 

The funds raised through the IPO will be utilised as follows:

• Capital Expenditure for Machinery: ₹6.0 crore
• Working Capital Requirements: ₹13.0 crore
• Repayment of Outstanding Borrowings: ₹1.0 crore
• General Corporate Purposes: Remaining amount

Business Overview

The company operates in pharmaceutical manufacturing and exporting having been in this business since 2019, specializing in healthcare products globally with diverse range including tablets, capsules, sachets, and syrups across various therapeutic categories. Asston Pharmaceuticals operates primarily in the pharmaceutical sector, providing formulations expertise through experienced promoters, wide range of products, strategic location, and skilled workforce with FDA certification by both Central and State FDA, NQA accreditation, and QMS standards compliance ensuring high-quality manufacturing for both direct sales and contract manufacturing on principle-to-principle approach with various marketers.